Ionis Pharmaceuticals (IONS) 2018-05-11T19:47:39+00:00

Ionis Pharmaceuticals (IONS)

Company Description

Ionis Pharmaceuticals is leading antisense drug discovery and development company with a large pipeline encompassing multiple therapeutics with potential value over a wide-range of disease areas.  The company currently has one marketed product, Kynamro, which is a treatment in familial hypercholesterolemia (HoFH); and the drug is under Phase III study in severe heterozygous familial hypercholesterolemia (HeFH).  Top-line pivotal study result releases of ISIS’s leading pipeline products, ISIS-APOCIIIRx in familial chylomicronemia syndrome (FCS) and severely high triglycerides (>880 mg/dL); ISIS-SMNRx in infant and children SMA patients; and ISIS-TTRRx in familial amyloid polyneuropathy (FAP), could start in 2016 and 2017 with possible approval and product launch in 2017 and beyond.  ISIS has one of the richest pipelines in the industry, with a total of more than 32 clinical programs in development at different clinical stages.

Published Reports

IONS-2018-05-07-1Q18
IONS-2018-05-11-AdComm voted favorably
IONS-2018-04-24-1Q18 Spinraza sales
IONS-2018-04-20-BIIB neurological deal is big
IONS-2018-04-02-Tafamidis could enter global TTR marketplace
IONS-2018-03-15-Akcea sells inotersen
IONS-2018-03-05-IONIS-HTTRx PII readout
IONS-2018-02-27-4Q17
IONS-2018-01-25-Robust 4Q17 Spinraza sales
IONS-2017-11-08-3Q17
IONS-2017-11-03-NEURO-TTR trial full data
IONS-2017-10-25-Mixed 3Q17 Spinraza sales
IONS-2017-10-06-Additional Spinraza clinical data
IONS-2017-08-14-Inoterson development rev
IONS-2017-08-09-2Q17 rev
IONS-2017-07-25-Robust 2Q17 Spinraza sales revenue
IONS-2017-07-10-Additional NEURO-TTR Study Topline Results
IONS-2017-05-16-NEURO-TTR data readout rev (2)
IONS-2017-05-2 IONS-Pharmaceuticals
IONS-2017-03-31-AKCEA-APO(a)-LRx P2 trial rev
IONS-2017-03-27-Akcea IPO rev
IONS-2017-03-13-IONS-IONS shares oversold rev
IONS-2017-03-06-IONS-FCS P3 positive rev
IONS-2017-03-02-IONS-FCS KOL call rev px
IONS-2017-02-28-IONS-4Q16 rev
IONS-2017-02-14-IONS-FXIRx development update rev
IONS-2017-01-17-Positive ENDEAR EOS data rev
IONS-2017-01-06-NVS-Akcea deal rev
IONS-2017-01-05-Pipeline update rev
IONS-2016-12-27-Spinraza approved rev2
IONS-2016-12-19-Positive Volanesorsen Compass results rev
ions-2016-12-05-mgmt-update-revions-2016-11-10-3q16-rev
ions-2016-11-07-cherish-interim-results-robust-rev
ions-2016-11-01-fxi-ph-ii-positive-rev
ions-2016-10-10-nusinersen-data-at-the-wms-rev
ions-2016-09-27-nusinersen-nda-submitted-rev
IONS-2016-08-10-2Q16 rev
IONS-2016-08-01-Nusinersen infant P3 positive rev
IONS-2016-07-14-RD day rev
IONS-2016-05-26-CARDIO-TTR stop rev
IONS-2016-05-05-1Q16 rev2 (2)
IONS-2016-05-03-Kynamro out-licensed
IONS-2016-04-22-AAN updates
IONS-2016-04-07-Clinical hold on CARDIO-TTR rev
IONS-2016-03-23-Favorable legal HCV decision
IONS-2016-02-26-4Q15
ISIS-2015-12-17-ISIS-TTRrx in wt-TTR Phase II initiation
ISIS-2015-11-10-3Q15 rev (1)
ISIS-2015-11-09-APO(a) update rev
ISIS-2015-11-04-TTR in FAC update
ISIS-2015-08-05-2Q15
ISIS-2015-06-22-SMA childhood P2 update
ISIS-2015-10-19-NDR
ISIS-2015-08-03-ISIS-New AZN deals rev
ISIS-015-07-21-ISIS-HTTRx P1-lla start rev
ISIS-2015-06-11-SMA P2 update rev
ISIS-2015-06-05-Akcea update rev
ISIS-2015-05-06-1Q15 rev
ISIS-2015-05-04-Bayer deal rev2
ISIS-2015-04-24-TTR in FAP update rev
ISIS-2015-02-03-ISIS-PTP1B P2 diabete data rev
ISIS-2015-02-27-4Q14 rev
ISIS-2015-01-06-ISIS-Increase TP rev4
ISIS-2014-12-08-ISIS-FXIRx full P2 data rev
ISIS-2014-11-25-Children SMA P3 trial start rev3
ISIS-2014-11-13-Increase TP rev
ISIS-2014-11-10-3Q14 rev
ISIS-2014-08-12-Initiation-Final
ISIS-2014-08-28-FCS P3 started rev
ISIS-2014-10-06-Model update rev
ISIS-2014-10-10-SMA P2 update rev